Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 3Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Endometrial Adenocarcinoma 1Bilateral Breast Carcinoma 1Adult Solid Neoplasm 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × ixabepilone × 1 year × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

NCT01375829 2026-04-13

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡